FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891237404> ?p ?o ?g. }

• W2891237404 endingPage "e0203046" @default.
• W2891237404 startingPage "e0203046" @default.
• W2891237404 abstract "Pulmonary vascular remodeling of pulmonary arterial hypertension (PAH) is characterized by an inappropriate increase of vascular cells. The receptor for advanced glycation end products (RAGE) is a type I single-pass transmembrane protein belonging to the immunoglobulin superfamily and is involved in a broad range of hyperproliferative diseases. RAGE is also implicated in the etiology of PAH and is overexpressed in pulmonary artery smooth muscle cells (PASMCs) in patients with PAH. We examined the role of RAGE in the inappropriate increase of PASMCs in patients with PAH.PASMCs were obtained from 12 patients with PAH including 9 patients with idiopathic PAH (IPAH) and 3 patients with heritable PAH (HPAH) (2 patients with BMPR2 mutation and one patient with SMAD9 mutation) who underwent lung transplantation. Western blot analysis and immunofluorescence staining revealed that RAGE and S100A8 and A9, ligands of RAGE, were overexpressed in IPAH and HPAH-PASMCs in the absence of any external growth stimulus. PDGF-BB (10 ng/mL) up-regulated the expression of RAGE in IPAH and HPAH-PASMCs. PAH-PASMCs are hyperplastic in the absence of any external growth stimulus as assessed by 3H-thymidine incorporation. This result indicates overgrowth characterized by continued growth under a condition of no growth stimulation in PAH-PASMCs. PDGF-BB stimulation caused a higher growth rate of PAH-PASMCs than that of non-PAH-PASMCs. AS-1, an inhibitor of TIR domain-mediated RAGE signaling, significantly inhibited overgrowth characterized by continued growth under a condition of no growth stimulation in IPAH and HPAH-PASMCs (P<0.0001). Furthermore, AS-1 significantly inhibited PDGF-stimulated proliferation of IPAH and HPAH-PASMCs (P<0.0001).RAGE plays a crucial role in the inappropriate increase of PAH-PASMCs. Inhibition of RAGE signaling may be a new therapeutic strategy for PAH." @default.
• W2891237404 created "2018-09-27" @default.
• W2891237404 creator A5013543347 @default.
• W2891237404 creator A5017013426 @default.
• W2891237404 creator A5019215192 @default.
• W2891237404 creator A5019802899 @default.
• W2891237404 creator A5021973822 @default.
• W2891237404 creator A5029975728 @default.
• W2891237404 creator A5037631569 @default.
• W2891237404 creator A5038761025 @default.
• W2891237404 creator A5043888002 @default.
• W2891237404 creator A5044544721 @default.
• W2891237404 creator A5048465309 @default.
• W2891237404 creator A5048936597 @default.
• W2891237404 creator A5058119107 @default.
• W2891237404 creator A5058610297 @default.
• W2891237404 creator A5059830493 @default.
• W2891237404 creator A5069940779 @default.
• W2891237404 creator A5083401692 @default.
• W2891237404 date "2018-09-04" @default.
• W2891237404 modified "2023-10-13" @default.
• W2891237404 title "Crucial role of RAGE in inappropriate increase of smooth muscle cells from patients with pulmonary arterial hypertension" @default.
• W2891237404 cites W1503258737 @default.
• W2891237404 cites W1972429205 @default.
• W2891237404 cites W1979770196 @default.
• W2891237404 cites W1993444466 @default.
• W2891237404 cites W1996442754 @default.
• W2891237404 cites W2004567083 @default.
• W2891237404 cites W2010171666 @default.
• W2891237404 cites W2014968448 @default.
• W2891237404 cites W2019063675 @default.
• W2891237404 cites W2079167630 @default.
• W2891237404 cites W2082570154 @default.
• W2891237404 cites W2088428562 @default.
• W2891237404 cites W2107766358 @default.
• W2891237404 cites W2110767986 @default.
• W2891237404 cites W2143453058 @default.
• W2891237404 cites W2149372547 @default.
• W2891237404 cites W2161439257 @default.
• W2891237404 cites W2167319946 @default.
• W2891237404 cites W2306880576 @default.
• W2891237404 cites W2318095272 @default.
• W2891237404 cites W2604234545 @default.
• W2891237404 cites W2805842770 @default.
• W2891237404 doi "https://doi.org/10.1371/journal.pone.0203046" @default.
• W2891237404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6122782" @default.
• W2891237404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30180189" @default.
• W2891237404 hasPublicationYear "2018" @default.
• W2891237404 type Work @default.
• W2891237404 sameAs 2891237404 @default.
• W2891237404 citedByCount "22" @default.
• W2891237404 countsByYear W28912374042019 @default.
• W2891237404 countsByYear W28912374042020 @default.
• W2891237404 countsByYear W28912374042021 @default.
• W2891237404 countsByYear W28912374042022 @default.
• W2891237404 countsByYear W28912374042023 @default.
• W2891237404 crossrefType "journal-article" @default.
• W2891237404 hasAuthorship W2891237404A5013543347 @default.
• W2891237404 hasAuthorship W2891237404A5017013426 @default.
• W2891237404 hasAuthorship W2891237404A5019215192 @default.
• W2891237404 hasAuthorship W2891237404A5019802899 @default.
• W2891237404 hasAuthorship W2891237404A5021973822 @default.
• W2891237404 hasAuthorship W2891237404A5029975728 @default.
• W2891237404 hasAuthorship W2891237404A5037631569 @default.
• W2891237404 hasAuthorship W2891237404A5038761025 @default.
• W2891237404 hasAuthorship W2891237404A5043888002 @default.
• W2891237404 hasAuthorship W2891237404A5044544721 @default.
• W2891237404 hasAuthorship W2891237404A5048465309 @default.
• W2891237404 hasAuthorship W2891237404A5048936597 @default.
• W2891237404 hasAuthorship W2891237404A5058119107 @default.
• W2891237404 hasAuthorship W2891237404A5058610297 @default.
• W2891237404 hasAuthorship W2891237404A5059830493 @default.
• W2891237404 hasAuthorship W2891237404A5069940779 @default.
• W2891237404 hasAuthorship W2891237404A5083401692 @default.
• W2891237404 hasBestOaLocation W28912374041 @default.
• W2891237404 hasConcept C104317684 @default.
• W2891237404 hasConcept C126322002 @default.
• W2891237404 hasConcept C134018914 @default.
• W2891237404 hasConcept C147990577 @default.
• W2891237404 hasConcept C169760540 @default.
• W2891237404 hasConcept C170493617 @default.
• W2891237404 hasConcept C180361614 @default.
• W2891237404 hasConcept C185592680 @default.
• W2891237404 hasConcept C24998067 @default.
• W2891237404 hasConcept C2775960820 @default.
• W2891237404 hasConcept C2776415932 @default.
• W2891237404 hasConcept C2778857457 @default.
• W2891237404 hasConcept C502942594 @default.
• W2891237404 hasConcept C55493867 @default.
• W2891237404 hasConcept C71924100 @default.
• W2891237404 hasConcept C86803240 @default.
• W2891237404 hasConceptScore W2891237404C104317684 @default.
• W2891237404 hasConceptScore W2891237404C126322002 @default.
• W2891237404 hasConceptScore W2891237404C134018914 @default.
• W2891237404 hasConceptScore W2891237404C147990577 @default.
• W2891237404 hasConceptScore W2891237404C169760540 @default.
• W2891237404 hasConceptScore W2891237404C170493617 @default.
• W2891237404 hasConceptScore W2891237404C180361614 @default.

• next